Stockscreener 앱 받기
643.59
0.10%
0.65
시간 외 거래:
643.86
0.27
+0.04%
전일 마감가:
$642.94
열려 있는:
$643.83
하루 거래량:
706.51K
Relative Volume:
1.24
시가총액:
$51.39B
수익:
$4.30B
순이익/손실:
$1.06B
주가수익비율:
49.22
EPS:
13.076
순현금흐름:
$1.04B
1주 성능:
-4.89%
1개월 성능:
-5.66%
6개월 성능:
+0.26%
1년 성능:
+37.36%
1일 변동 폭
$636.36
$651.35
1주일 범위
$622.37
$682.99
52주 변동 폭
$356.14
$769.98
아이덱스 래버러토리스 Stock (IDXX) Company Profile
명칭
Idexx Laboratories Inc
전화
(207) 556-0300
주소
ONE IDEXX DRIVE, WESTBROOK, ME
IDXX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
643.59 | 51.34B | 4.30B | 1.06B | 1.04B | 13.08 |
|
TMO
Thermo Fisher Scientific Inc
|
542.36 | 212.36B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
215.75 | 155.19B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
A
Agilent Technologies Inc
|
129.64 | 37.70B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
180.96 | 34.49B | 15.90B | 1.28B | 2.21B | 7.2842 |
아이덱스 래버러토리스 Stock (IDXX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-31 | 업그레이드 | Stifel | Hold → Buy |
| 2025-10-01 | 개시 | UBS | Neutral |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-01 | 개시 | Jefferies | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | BTIG Research | Buy |
| 2024-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-12-04 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2023-08-02 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-07-12 | 개시 | Piper Sandler | Overweight |
| 2022-05-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-08 | 개시 | Atlantic Equities | Overweight |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-17 | 개시 | Barclays | Overweight |
| 2019-09-09 | 개시 | Goldman | Neutral |
| 2019-05-23 | 개시 | Guggenheim | Buy |
| 2018-11-02 | 재확인 | BofA/Merrill | Buy |
| 2018-05-07 | 재확인 | Stifel | Buy |
| 2018-01-16 | 개시 | Piper Jaffray | Overweight |
| 2017-08-23 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | 업그레이드 | CL King | Neutral → Buy |
| 2017-02-03 | 다운그레이드 | Feltl & Co. | Hold → Sell |
| 2016-09-29 | 재개 | BofA/Merrill | Neutral |
| 2016-08-16 | 재확인 | Stifel | Buy |
| 2016-08-03 | 업그레이드 | Northcoast | Sell → Neutral |
| 2016-07-20 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-19 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-01 | 개시 | CL King | Neutral |
| 2016-03-21 | 재확인 | Stifel | Buy |
| 2016-02-04 | 개시 | Credit Suisse | Outperform |
| 2015-10-29 | 재확인 | Stifel | Buy |
| 2015-08-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | 재확인 | Stifel | Buy |
| 2015-07-23 | 재확인 | Canaccord Genuity | Buy |
모두보기
아이덱스 래버러토리스 주식(IDXX)의 최신 뉴스
Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating - marketscreener.com
4 Analysts Have This To Say About IDEXX Laboratories - Benzinga
IDEXX Laboratories (IDXX) Positioned to Benefit from Growing Aging Pet Market - Finviz
Fidelity Growth Strategies Fund Avoids IDEXX Laboratories (IDXX) Due to Questionable Growth Durability - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Idexx Laboratories (IDXX) and West Pharmaceutical Services (WST) - The Globe and Mail
Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 - marketscreener.com
Idexx Laboratories executive vice president sells $4.6 million in stock - MSN
IDEXX: A Great Business Trapped By A Demanding Valuation (NASDAQ:IDXX) - Seeking Alpha
Hantz Financial Services Inc. Decreases Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Alta Capital Management LLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Rep. April McClain Delaney Sells Off Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Lonza Group (OtherLZAGY) - The Globe and Mail
A Quick Look at Today's Ratings for IDEXX Laboratories Inc(IDXX.US), With a Forecast Between $730 to $805 - 富途牛牛
IDEXX Laboratories Analysts Cut Their Forecasts Following Q4 Results - Benzinga
Roku To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 - marketscreener.com
UBS Adjusts IDEXX Laboratories PT to $730 From $750 - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 earnings call transcript - MSN
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 Earnings Call Transcript - Insider Monkey
BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 - marketscreener.com
IDEXX Laboratories, Inc. $IDXX Shares Sold by Villere ST Denis J & Co. LLC - MarketBeat
Thrivent Financial for Lutherans Has $38.68 Million Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories: Can This Quiet Diagnostics Powerhouse Still Surprise Wall Street? - AD HOC NEWS
BTIG Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $800 - 富途牛牛
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 14.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips - Investing.com Canada
IDEXX Laboratories (NASDAQ:IDXX) Trading Down 6.9%Should You Sell? - MarketBeat
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories Inc (IDXX) Q4 2025 Earnings Call Highlights: - GuruFocus
IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise - The Globe and Mail
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - 富途牛牛
Why Is IDEXX Labs Stock Falling Today? - Benzinga
IDEXX Laboratories Q4 Earnings Call Highlights - MarketBeat
IDEXX Laboratories (IDXX) Reports Strong Q4 2025 Performance - GuruFocus
RSI Alert: Idexx Laboratories (IDXX) Now Oversold - Nasdaq
IDEXX Laboratories Reports 14% Q4 Revenue Growth Driven by Premium Instrument Placements - Market Business Insights
IDEXX falls 4% following in-line 2026 guidance - Seeking Alpha
IDEXX beats the Street on Q4 results, issues initial 2026 guidance - Mainebiz
AI for investors - MLQ.ai
IDEXX Laboratories (NASDAQ:IDXX) Updates FY 2026 Earnings Guidance - MarketBeat
Earnings Summary: IDEXX Laboratories Q4 - Benzinga
IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics - marketscreener.com
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
IDEXX Laboratories (IDXX) Q4 FY25 sales rise in double digits - AlphaStreet
IDEXX Laboratories (NASDAQ:IDXX) Announces Quarterly Earnings Results - MarketBeat
IDEXX LABORATORIES INC (NASDAQ:IDXX) Reports Strong Q4 2025 Earnings Beat, Issues Cautious 2026 Outlook - Chartmill
IDEXX Laboratories Q4 Comparable Earnings, Revenue Rise; Issues 2026 Guidance - marketscreener.com
Idexx: Q4 Earnings Snapshot - Bitget
IDEXX LABS ($IDXX) Releases Q4 2025 Earnings - Quiver Quantitative
아이덱스 래버러토리스 (IDXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
0.75%
자본화:
|
볼륨(24시간):